Cat. No.
MABL-3674
Application
deplete
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
KW-0761 (Mogamulizumab)
From
Recombinant Antibody
Specificity
This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.
Alternative Names
CD194; CKR-4; CCR-4; CCR4; K5-5
UniProt
P51679
Immunogen
This antibody was prepared by humanization of a mouse anti-CCR4 mAb.
Application Notes
The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8% and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action; in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated.
Antibody First Published
Yamamoto et al. Phase I study of KW-0761, a defucosylated humanized anti- CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma (Yamamoto, 2010) Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 March 2010, Vol.28(9), pp.1591-8 PMID:
Note on publication
Imai et al (1999) describes the use of a mouse anti-CCR4 antibody to isolate CCR4+cells using labelling and FC studies. Yamamoto et al (2010) descibes the successful testing of the humanized, defucosylated form of this anti-CCR4 antibody in a phase I trial.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
